

TRIAL SCHEDULE 2018-2019

Planned trial issues per financial year	Immune Monitoring (IM) Accredited	Immune Monitoring_Alternate Technologies (IM-AT) - Accredited	CD34 Stem Cell Enumeration (CD34) - Accredited	Leukaemia Immunophenotyping Part 1 (LI) - Accredited	Leukaemia Diagnostic Interpretation Part 2 (LDI) - Accredited	Paroxysmal Nocturnal Haemoglobinuria (PNH) - Accredited	Low Level Leucocyte Enumeration (LLL) - Accredited	Minimal Residual Disease In B-ALL (MRD-ALL) - Accredited	Minimal Residual Disease In CLL (MRD-CLL) - Not Accredited	Minimal Residual Disease In AML (MRD-AML) - Not Accredited	Pilot Minimal Residual Disease In Multiple Myeloma (MRD-MM) - Not Accredited	Pilot Haematological Malignancy Bone Marrow Aspirate Assessment (HMBA) - Not Accredited	Pilot CSF Programme- Not Accredited
APRIL 2018			X	X	X	X	X		X		X		
MAY 2018	X	X			X								X
JUNE 2018			X	X		X	X					X	
JULY 2018	X	X			X			X					
AUGUST 2018			X	X		X	X						X
SEPTEMBER 2018	X	X			X					X		X	
OCTOBER 2018			X	X	X	X	X		X				
NOVEMBER 2018	X	X			X			X					
DECEMBER 2018			X	X		X	X			X		X	
JANUARY 2019	X	X			X			X					X
FEBRUARY 2019			X	X			X				X		
MARCH 2019	X	X			X	X			X			X	

Please note that this is a guide only. UK NEQAS for Leucocyte Immunophenotyping reserves the right to cancel or vary the number of shipments. Please note that your participation entitles you to the service and not the number of shipments.

Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS proficiency testing provider No. 7804, operating UK NEQAS for Leucocyte Immunophenotyping.